Device Innovation Team
1.Usage of vial & syringe is associated with:
Complication
More time consuming
Error Prone
All of the above
3. The features of NovoPen® 4 include:
Short injection movement
Low force to inject dose and Easy dose adjustment
Easy to read dose scale
All of the above
4. Mixtard® 30, pre-mix insulin gives ______________ glucose control
Both fasting and prandial
Only Fasting
Only prandial
Neither fasting nor prandial
5. The difference between biological and chemical medicines are:
Higher variability, and more complex
Have the potential to provoke immune reactions
Biological medicines need special transport and storage conditions
All of the above
6. Which of the following are alternative names for Biosimilars?
Biogenerics
Follow-on protein
Follow-on Biologic
All of the above
7. Which of the following countries do not have regulatory guidelines for Biosimilars?
USA
Malaysia
Turkey
Japan
8. Which of the following statements is true with respect to biosimilars?
Biopharmaceuticals are very sensitive to temperature changes and/or shaking
Strict storage and handling conditions are therefore essential for maintaining product integrity and stability
Poor adherence to (cold) and safety
All of the above
9. NovoFine® needles are associated with
Less pain (shorter & thinner)
Less anxiety
Easy to attach/detach
All of the above
11. Every ____% drop in HbA1c can reduce long-term diabetes complications (UKPDS: Stratton et al. BMJ 2000;32:405–1)
3%
1%
5%
2%
13. Mixtard® 30 has an onset of action within ___min, peak within ____ hrs with a duration of action of upto ___hrs.
30min, 2-8hrs, upto 24hrs
10min, 2-4hrs, upto 24 hrs
15min, 1-2hrs, upto 14hrs
None of the above
14. NovoPen®4, as compared to competition, has,
4-times larger dose setting window
Metallic body with best design
50% less force as compared to other devices
All of the above
15. The aim of Diabetes treatment is to provide:
Maintain near-normal glycemia
Minimize long-term complications, both microvascular and macrovascular
Improve quality of life
All of the above
16. Which of the following is true for Insulin?
Insulin, a polypeptide hormone - Genetically engineered through r-DNA technology
Highly unstable and has to be produced in controlled formulation processes
Batch-to-batch consistency is critical, due to its daily usage as an injection.
All of the above
17. Which of the following are true?
Mixtard® is available in Mixtard® Flexpen
Mixtard® is available in Mixtard® Penfill
Mixtard® Penfill is compatible with NovoPen4
All of the above
18. Mixtard® comprises of ______and ______ acting components.
Rapid acting component only
Long acting component only
Rapid acting and long acting components
Neither rapid acting nor long acting
19. Risk of double-dosing of insulin means:
Having hyperglycaemia
Future diabetes complications
Having hypoglycaemia
Decrease in insulin dose
22. Primary factors related to patient awareness of injection discomfort are:
Needle diameter
Needle length
Noise
All of the above
23. BLA stands for
Biologics License Application
Biosimilar License Authority
Biologics Local Authority
Biosimilar Local Application
26. According to . Isreal –Bultman et al study, which of the following is true?
Patients prefer NP4 after switching from other devices
Treatment satisfaction improved after shifting to NP4
Both a) and b)
Only a)
27. According to Donsmark et al study, which of the following is true?
Low dose force of NP4 after simulated use of 5 years
Patients prefer NP4 after switching from other devices
Treatment satisfaction improved after shifting to NP4
Accuracy OF NP4
28. According to Kirstensen and Donsmark et al study, which of the following are true?
Low dose force of NP4 after simulated use of 5 years
Patients prefer NP4 after switching from other devices
AccuraCY OF NP4
Both a) and c)
29. According to Asakura et al. study, which of the following is true?
FlexPen® delivered doses closer to target compared with vial and syringe
Significantly better accuracy with Next Generation FlexPen® † compared with SoloSTAR®
Lower dose force with Next Generation FlexPen® † compared with SoloSTAR® and KwikPen
Both a) and c)
30. According to - Lee et al. study, which of the following is true?
FlexPen® delivered doses closer to target compared with vial and syringe
Significantly better accuracy with Next Generation FlexPen® † compared with SoloSTAR®
Lower dose force with Next Generation FlexPen® † compared with SoloSTAR® and KwikPen
Significantly higher adherence when using FlexPen® compared with vial and syringe
31. In NN, we follow any applicable laws, regulations and industry codes. We also follow our own business ethics standards and procedures (Novo Nordisk Code of Conduct). According to the Business Ethics Code of Conduct, which of the following statements is correct?
Local law and industry code may be disregarded, if my local legal department approves it
Novo Nordisk standards and procedures may be overruled if more stringent rules apply locally
Either of the above
32. An employee invites an HCP as a speaker for a meeting to be held on 20th August 2017. You send the request for contract preparation to the legal department by filling up the contract initiation template. Amount to be paid for the services is INR 50,000. When you will calculate FMV?
At the time of payment
At the time of preparation of the contract
Either of the above
None of the above
33. In a Sponsorship, the following is acceptable:
Payment routed to HCP’s directly need not include any follow up documentation.
While Sponsoring an event, commercial benefit for Novo Nordisk and disclosure of the fact that the event has been sponsored by Novo Nordisk is not required if sponsorship amount is below INR 5,00,000.00.
"Follow up on fund utilisation is not required if sponsorship amount is below INR 5,00,000.00.
The commercial benefit to Novo Nordisk, disclosure of the fact that the event has been sponsored by Novo Nordisk, agreement and proper follow-up documentation from the institution.
34. Ryzodeg meeting took place on 1st July 2017. Timings as per agenda was 8:00 to 10:00 PM, with dinner scheduled from 9:30 to 10:00 PM. Due to unavoidable circumstances, meeting started at 8:30 PM. Meeting ended at 10:45 pm. But hotel invoice was generated at 12:00 pm. How will you abide by 75/25 rule for the scientific meeting?
I will inform Manager and pay the hotel as per his instructions
I will pay the hotel and thereafter raise exception for deviation from 25/75 rule and document the reason for delay in the start of the meeting
There is no deviation as such in the situation as it occurred due to unavoidable circumstances
None of the above
35. An employee invites a doctor (HCP) as a speaker for a meeting. The HCP accepts the invitation. He is accompanied to the meeting by his friend, who is also a doctor and practices in the field of endocrinology.
It can be accommodated as the friend is also a doctor.
Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies.
Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies. If the friend still attends the event, you should document it
36. Which of the following factors are considered for career progression from a Product Specialist to a Sr product specialist?
3P Rating
Minimum years of experience
Recommendation form Line manager
All of the above
37. Which of the following options regarding Goal Setting is completely TRUE for 2018 process:
Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 5 goals with minimum 10% weight;
Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 10 goals with minimum 5% weight;
Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 10 goals with minimum 5% weight;
Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 12 goals with minimum 5% weight;
38. Which of the following statements is FALSE for 2018 performance management process:
Your performance rating will impact your annual salary increase
Your performance rating will not impact your selection to development programmes
Your 3P rating will serve as an input for career progression
Your performance rating will be solely decided by your manager’s discretion
40. Which of the following statements is true for 2018 Talent Development Program Nomination?
Your performance rating will be considered for your nomination
Your performance rating along with manager’ inputs will be considered for your nomination
Your cumulative health score card will be considered for your nomination
Your sales performance will be considered for your nomination
41. All employees should report any customer complaint (Product defect/AE/SAE) or safety information to
Safety Team (INAGREE@novonordisk.com)
GM (General Manager)
HQ (Head Quarters)
None of the above
42. Which of the below need to be reported
Use of NN product in pregnancy
Any technical complaint
Any adverse Event
All the above
43. If an HCP requests for off label information you should contact
GM
Medical Department
Finance Department
Do not know
44. In case if you observe errors in label, promotional material contact
Line Manager & QA
No need to report to any one
Distribute to HCP with error
Do not know
45. Corrections to printed or handwritten data must be made so that the original text is:
Strikethrough so nothing is readable
Strikethrough but readable
Completely covered using a whitener
Enter duplicate data
46. What is the Incentive amount you are eligible at 100% sales achievement p.a (Both Sales & Activity)?
200000
250000
700000
None of the Above
{"name":"Device Innovation Team", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"Usage of vial & syringe is associated with:, The Mixtard® 30 FlexPen® is:, The features of NovoPen® 4 include:","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}